Abstract
Circulating tumour cells (CTCs) could escape the host immune surveillance by altering the expression of immune regulatory molecules (PD-L1, PD-L2, CTLA-4, CD47) in cancer patients. Recent studies suggested that KRAS mutation might promote the immune escape of tumour cells by inducing the upregulation of these molecules. However, the regulatory effects of KRAS on the expression of CTLA-4 in patients with colorectal cancer (CRC) have yet to be explored. This study aimed to investigate KRAS and CTLA-4 mRNA expression profiling in CTCs from patients with CRC.
Original language | English |
---|---|
Pages | S1389 |
Number of pages | 1 |
Publication status | Published - Oct 2022 |
Event | Molecular Analysis for Precision Oncology Congress 2020: MAP 2020 - Amsterdam Conference Centre Beurs van Berlage, Amsterdam, Netherlands Duration: 14 Oct 2022 → 16 Oct 2022 https://www.esmo.org/meeting-calendar/past-meetings/map-2022 |
Conference
Conference | Molecular Analysis for Precision Oncology Congress 2020 |
---|---|
Country/Territory | Netherlands |
City | Amsterdam |
Period | 14/10/22 → 16/10/22 |
Other | MAP is the leading global meeting dedicated to precision oncology, defined as molecular profiling of tumours to identify targetable alterations. This oncology field is fast evolving and has now entered the mainstream of clinical practice. At MAP, international key opinion leaders explain how to use genomic data for treating cancer patients, matching such data to a specific drug or therapy, based on the genetic drivers detected in the patients’ tumours, and they debate about future challenges in precision oncology. The 2022 edition of the Congress offered participants the option to attend in person, in Amsterdam, or online, through a virtual platform, from 14 to 16 October 2022, thanks to the new Live PLUS congress format. The MAP Congress is the result of a solid partnership among Cancer Research UK (CRUK), the European Society for Medical Oncology (ESMO) and Unicancer, all committed to offering the best care to people with cancer worldwide, through oncology education and research. |
Internet address |